Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteriaEur. J. Cancer 2022 Sep 01;173(2022)285-296, J Larkin, J Weber, M Del Vecchio, H Gogas, AM Arance, S Dalle, CL Cowey, M Schenker, JJ Grob, V Chiarion-Sileni, I Márquez-Rodas, MO Butler, AM Di Giacomo, MR Middleton, L De la Cruz-Merino, P Arenberger, V Atkinson, A Hill, LA Fecher, M Millward, NI Khushalani, P Queirolo, GV Long, M Lobo, M Askelson, PA Ascierto, M Mandalá
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.